Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: J Invest Dermatol. 2015 Aug 24;135(12):3115–3124. doi: 10.1038/jid.2015.329

Figure 3. Vemurafenib and TGF-β co-operate to release growth factors from primary human fibroblasts.

Figure 3

A ELISA data showing NRG release from 3 human skin fibroblast cell lines, following treatment with TGF-β (100 pg and 1 ng/ml) for 72 hours. B: ELISA data showing HGF release from 3 human skin fibroblast cell lines, following treatment with vemurafenib (3 μM, 72 hrs). C: Western blot analysis showing vemurafenib (3 μM) to induce paradoxical MAPK signaling in primary human skin fibroblasts that could be blocked through combination with trametinib (10 nM). D: ELISA data showing HGF release from 2 human skin fibroblast cell lines, following 72-hour treatment with 3 μM vemurafenib, 10nM Trametinib, or the combination.